This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a study to determine the safety of an anti-IgE momoclonal antibody (Omalizumab, also called Xolair) in treating children with moderate to severe atopic dermatitis and food allergies. The dosing phase will last three to six months, and follow-up will continue for two yrs to determine if Xolair has any effect in reducing the development of hay fever and asthma.
Showing the most recent 10 out of 589 publications